Acadia Healthcare Company Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

false 0001520697 0001520697 2025-10-30 2025-10-30

 

 

 

 

 

 

Date of report (Date of earliest event reported): November 5, 2025 (October 30, 2025)

 

 

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

(Registrant’s Telephone Number, including Area Code)

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company         ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.                                                         ☐

 

 

 

On November 5, 2025, Acadia Healthcare Company, Inc. (“Acadia” or the “Company”) issued a press release announcing, among other things, Acadia’s operating and financial results for the third quarter ended September 30, 2025. The press release is furnished herewith as Exhibit 99 hereto and is incorporated herein by reference.

 

Item 5.02          Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On October 30, 2025, Dr. Nasser Khan notified the Company of his resignation as Chief Operating Officer (“COO”) of the Company, effective November 3, 2025. In connection with his resignation as COO, the Company entered into a transition and separation agreement (the “Khan Transition and Separation Agreement”) with Dr. Khan. Pursuant to the Khan Transition and Separation Agreement, Dr. Khan will be employed as an executive advisor to the Company’s Chief Executive Officer through December 31, 2025, and shall receive a lump-sum payment of $515,000 no later than March 15, 2026. In addition, Dr. Khan will remain eligible to earn a cash bonus for the 2025 performance year, determined based on actual performance achievement, as determined by the Board or the Compensation Committee in its sole discretion.

 

The Company has initiated a search for a new COO and, in the interim, Dr. Khan’s former COO duties are being assumed by other members of the Company’s executive leadership team.

 

The foregoing description of the Khan Transition and Separation Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Khan Transition and Separation Agreement, a copy of which is attached hereto as Exhibit 10 and incorporated by reference herein.

 

 

 

 

 

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.